Loading
AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.
AZD4045 is a CAR-T cell therapy developed by AstraZeneca. Its target is BCMA (the sponsor names BCMA). The sponsor states: An allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA). ClinicalTrials.gov describes the intervention as: Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT07681596, plans to enrol 101 participants with primary completion expected 2031-03-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA). Connects to BCMA.
1.AZD4045 slips into a pocket on BCMA.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD4045" OR ABSTRACT:"AZD4045") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD4045, not a curated reading list.
Shares BCMA, Multiple myeloma and the tag pipeline.
Shares BCMA, AstraZeneca, Multiple myeloma and the tag pipeline.
Shares AstraZeneca, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.